why mesoblast will drop substantially , page-94

Teva have been front and centre behind the redesign of the CHF FDA clinical trials, so it made no sense that they'd be leaving the CHF trials. (they still hold equity in MSB and have other trial application interests)

I've seen when this kind of thing which happened defied logic, where companies suddenly decide to run a ruler down all projects and then divest. It bore no relationship with what it had done previously. The left hand didn't know what the right hand was doing.

It's a discussion room and you should tolerate a diversity of views.

Teva are taking a vicious approach to risk, having got it spectacularly wrong on their DRUG interests. someone in power is going overboard and focussing only on generic drugs.. It's fallout from Teva going wrong and overcorrecting. It's a major departure from what they could be expected to do as they should understand the science behind stem cells and the much massively reduced risk is involved. Some very narrow minded peoples are in charge there.

Sure it's a black swan event. Risk is mostly baked out of MSB with the science, and certainly I don't see this as fatal in terms of capital raising. We are in a very choppy market but inevitably there will be a JV.

Teva are acting in an absurd way. I have explained why it's an over reaction several times. Sure I didn't think they would be that stupid, but I've seen this happen before where there is an illogical decision and the company involved regretted it.

As a LT holder I don't think it's fatal to MSB.

The draw down facility is a back stop for MSB; it may not be needed. Other irons are in the fire.

I don't apologise for offering an alternate opinion to the cacophony of negative views in here, many of which are poorly thought out insults which you see no need to correct.